Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PST-101
- Development stage
- Preclinical
- Lead developer
- Piston Bio
- Modality
- Small Molecules
01
Overview
PST-101 is a brain-penetrant small molecule adenosine A2A receptor antagonist being developed by Piston Bio for the treatment of cancer-related apathy. The drug is designed to modulate dopaminergic signaling within the central nervous system to restore motivational function in patients experiencing apathy associated with cancer. As of March 2026, Piston Bio has aligned with the FDA on the design of a proposed Phase 2 study and plans to submit an Investigational New Drug (IND) application in 2026. PST-101 represents a potential first-in-class therapy for this indication, targeting the neural mechanisms that regulate motivation and metabolic function.
02
Targets
ADORA2A (Adenosine A₂A Receptor)
Beyond the preview
Go deeper on PST-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PST-101.